WO2022031150A1 - Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle - Google Patents

Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle Download PDF

Info

Publication number
WO2022031150A1
WO2022031150A1 PCT/KR2021/010517 KR2021010517W WO2022031150A1 WO 2022031150 A1 WO2022031150 A1 WO 2022031150A1 KR 2021010517 W KR2021010517 W KR 2021010517W WO 2022031150 A1 WO2022031150 A1 WO 2022031150A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
cell
antibody
conjugate
cancer
Prior art date
Application number
PCT/KR2021/010517
Other languages
English (en)
Korean (ko)
Inventor
정두영
이진수
조현용
이병성
Original Assignee
주식회사 피노바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 피노바이오 filed Critical 주식회사 피노바이오
Publication of WO2022031150A1 publication Critical patent/WO2022031150A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un conjugué comprenant : une désoxycytidine pouvant traverser la membrane cellulaire, activée sous une forme triphosphate dans une cellule ; et un lieur contenant un éther de silyle dont une extrémité est liée à un groupe hydroxyle d'un médicament, le groupe hydroxyle du médicament lié au groupe éther de silyle étant un site de clivage par acide, et dans une atmosphère acide (pH ≤ 7), le groupe éther de silyle lié au groupe hydroxyle du médicament étant décomposé de telle sorte que le médicament est libéré sous forme libre.
PCT/KR2021/010517 2020-08-07 2021-08-09 Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle WO2022031150A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200099238 2020-08-07
KR10-2020-0099238 2020-08-07

Publications (1)

Publication Number Publication Date
WO2022031150A1 true WO2022031150A1 (fr) 2022-02-10

Family

ID=80118393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/010517 WO2022031150A1 (fr) 2020-08-07 2021-08-09 Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle

Country Status (2)

Country Link
KR (1) KR20220018954A (fr)
WO (1) WO2022031150A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337267A (zh) * 2022-08-15 2022-11-15 中国科学技术大学 一种基于脂质体纳米囊泡的酸响应型药物递送平台的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012327A2 (fr) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Composes chimiques
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
KR20180115330A (ko) * 2016-03-02 2018-10-22 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012327A2 (fr) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Composes chimiques
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
KR20180115330A (ko) * 2016-03-02 2018-10-22 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FINNISS MATHEW C., KEVIN S. CHU, CHARLES J. BOWERMAN, J. CHRISTOPHER LUFT, ZISHAN A. HAROON, JOSEPH M. DESIMONE: " A versatile acid-labile linker for antibody–drug conjugates", MEDICINAL CHEMISTRY COMMUNICATIONS, vol. 5, no. 9, 1 January 2014 (2014-01-01), pages 1355 - 1358, XP055895653 *
MINI E., S NOBILI, B CACIAGLI, I LANDINI, T MAZZEI: "Cellular pharmacology of gemcitabine", ANNALS OF ONCOLOGY, vol. 17, 31 May 2006 (2006-05-31), XP055895651, DOI: 10.1093/annonc/mdj941 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337267A (zh) * 2022-08-15 2022-11-15 中国科学技术大学 一种基于脂质体纳米囊泡的酸响应型药物递送平台的制备方法及其应用
CN115337267B (zh) * 2022-08-15 2023-10-20 中国科学技术大学 一种基于脂质体纳米囊泡的酸响应型药物递送平台的制备方法及其应用

Also Published As

Publication number Publication date
KR20220018954A (ko) 2022-02-15

Similar Documents

Publication Publication Date Title
AU2018200308B2 (en) Antibody-drug conjugate
KR102638901B1 (ko) 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
WO2015182984A1 (fr) Composé contenant un groupe auto-immolable
WO2013125891A1 (fr) Anticorps modifié dans lequel un motif comportant un résidu cystéine est lié, conjugué anticorps modifié-médicament comportant l'anticorps modifié, et son procédé de fabrication
WO2018182341A1 (fr) Précurseur dimère de pyrrolobenzodiazépine et composé conjugué ligand-lieur associé
WO2020180121A1 (fr) Conjugués anticorps-médicament comprenant un anticorps contre dlk1 humain et utilisation associée
KR102189731B1 (ko) 피롤로벤조디아제핀 컨쥬게이트
US20240109916A1 (en) Cytotoxic agents
AU2018271751B2 (en) Anti-human interleukin-2 antibodies and uses thereof
KR20140010067A (ko) 컨쥬게이트의 제조방법
CA3194672A1 (fr) Conjugues de medicament et d'element d'affinite
WO2018174544A2 (fr) Anticorps se liant spécifiquement à muc1 et son utilisation
WO2022031150A1 (fr) Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle
CN112739341A (zh) 抗cd2抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2019212253A1 (fr) Anticorps se liant de manière spécifique à c-met et utilisation associée
WO2021201654A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de la mucosite induite par une radiothérapie, une chimiothérapie ou une combinaison de celles-ci, comprenant des dérivés de glp-2 ou un conjugué à action prolongée de ceux-ci
WO2022211508A1 (fr) Conjugué anticorps-médicament comprenant un anticorps dirigé contre la cldn18.2 humaine et utilisation associée
WO2020141923A9 (fr) Composé dimère de pyrrolobenzodiazépine présentant une sécurité améliorée et son utilisation
WO2021101349A1 (fr) Anticorps se liant à ror1 et à b7-h3, conjugué anticorps-médicament le contenant et utilisation associée
WO2022149837A1 (fr) Anticorps anti-fgfr3 et son utilisation
WO2022124866A1 (fr) Anticorps anti-pd-1 et ses utilisations
WO2022124864A1 (fr) Anticorps anti-tigit et son utilisation
WO2023080695A1 (fr) Anticorps spécifique de la résistine et son utilisation
WO2022245186A1 (fr) Conjugué anticorps-médicament qui se lie à ror1 et b7-h3, et utilisation de celui-ci
WO2023157989A1 (fr) Conjugué anticorps-médicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21854557

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21854557

Country of ref document: EP

Kind code of ref document: A1